EGFR and ameloblastoma: In primary ameloblastoma cells, treatment with EGFR monoclonal antibodies (cetuximab and panitumumab) or EGFR tyrosine kinase inhibitors (erlotinib, gefitinib and AG1478) suppressed cell growth, suggesting these therapies are effective for the treatment of a subset of ameloblastomas [1].